Evidence map›Paper›PMID 26067277›Full record

ReviewCancer immunology, immunotherapy : CII2015

Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer.

Gregor Sersa, Justin Teissie, Maja Cemazar, Emanuela Signori, Urska Kamensek, Guillermo Marshall, Damijan Miklavcic

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in Cancer immunology, immunotherapy : CII, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06388252 (Electrochemotherapy Induces Changes in the Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Patients With Cutaneous Melanoma), which is not on this map. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
19.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06388252 naenrolling by invitationnot on this mapstarted 2023, after this paper: background citation

Electrochemotherapy Induces Changes in the Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Patients With Cutaneous Melanoma

TypeinterventionalSponsorInstitute of Oncology LjubljanaRan2023 to 2026Enrolled10ConditionsCutaneous Malignant MelanomaArmsElectrochemotherapy with Intratumoral Cysplatin, Electrochemotherapy with Intravenous Bleomycin
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 4 countries.

Gregor SersaDepartment of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska 2, 1000, Ljubljana, Slovenia, gsersa@onko-i.si.
Justin Teissie
Maja Cemazar
Emanuela Signori
Urska Kamensek
Guillermo Marshall
Damijan Miklavcic
Institute of Oncology Ljubljana · SICentre National de la Recherche Scientifique · FRConsejo Nacional de Investigaciones Científicas y Técnicas · ARIstituto di Farmacologia Traslazionale · ITUniversity of Ljubljana · SIUniversity of Primorska · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Electroporation is a platform technology for drug and gene delivery. When applied to cell in vitro or tissues in vivo, it leads to an increase in membrane permeability for molecules which otherwise cannot enter the cell (e.g., siRNA, plasmid DNA, and some chemotherapeutic drugs). The therapeutic effectiveness of delivered chemotherapeutics or nucleic acids depends greatly on their successful and efficient delivery to the target tissue. Therefore, the understanding of different principles of drug and gene delivery is necessary and needs to be taken into account according to the specificity of their delivery to tumors and/or normal tissues. Based on the current knowledge, electrochemotherapy (a combination of drug and electric pulses) is used for tumor treatment and has shown great potential. Its local effectiveness is up to 80 % of local tumor control, however, without noticeable effect on metastases. In an attempt to increase systemic antitumor effectiveness of electrochemotherapy, electrotransfer of genes with immunomodulatory effect (immunogene electrotransfer) could be used as adjuvant treatment. Since electrochemotherapy can induce immunogenic cell death, adjuvant immunogene electrotransfer to peritumoral tissue could lead to locoregional effect as well as the abscopal effect on distant untreated metastases. Therefore, we propose a combination of electrochemotherapy with peritumoral IL-12 electrotransfer, as a proof of principle, using electrochemotherapy boosted with immunogene electrotransfer as in situ vaccination for successful tumor treatment.

Indexed as

ElectrochemotherapyAnimalsDrug Delivery SystemsGene Transfer TechniquesHumansInterleukin-12NeoplasmsVaccinationInterleukin-12

Identifiers

PMID26067277
PMCPMC4554735
OpenAlexW1875213919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.